{"id":"NCT00083889","sponsor":"Pfizer","briefTitle":"SU011248 Versus Interferon-Alfa As First-Line Systemic Therapy For Patients With Metastatic Renal Cell Carcinoma","officialTitle":"A Phase 3, Randomized Study Of SU011248 Versus Interferon-Alfa As First-Line Systemic Therapy For Patients With Metastatic Renal Cell Carcinoma","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2004-08","primaryCompletion":"2008-09","completion":"2008-09","firstPosted":"2004-06-04","resultsPosted":"2009-12-10","lastUpdate":"2010-01-26"},"enrollment":750,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Carcinoma, Renal Cell"],"interventions":[{"type":"DRUG","name":"Interferon-alfa","otherNames":["Roferon"]},{"type":"DRUG","name":"SU011248","otherNames":["Sunitinib, SUTENT"]}],"arms":[{"label":"2","type":"ACTIVE_COMPARATOR"},{"label":"1","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to test whether SU011248 has activity and is safe compared to interferon-alfa as first-line therapy in patients with metastatic renal cell carcinoma (RCC).","primaryOutcome":{"measure":"Progression-Free Survival (PFS), Core Radiology Assessment","timeFrame":"Day 28 of each 6-week cycle: duration of treatment phase","effectByArm":[{"arm":"SU011248","deltaMin":48.3,"sd":null},{"arm":"IFN-Î±","deltaMin":22.1,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.0001"},{"comp":"OG000 vs OG001","p":"<.00001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":3},"locations":{"siteCount":123,"countries":["United States","Australia","Brazil","Canada","France","Germany","Italy","Poland","Russia","Spain","United Kingdom"]},"refs":{"pmids":["29853320","28410911","27238653","25577718","20104222","17215529"],"seeAlso":["https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A6181034&StudyName=SU011248%20Versus%20Interferon-Alfa%20As%20First-Line%20Systemic%20Therapy%20For%20Patients%20With%20Metastatic%20Renal%20Cell%20Carcinoma%20%20"]},"adverseEventsSummary":{"seriousAny":{"events":170,"n":375},"commonTop":["Fatigue","Nausea","Diarrhoea","Anorexia","Dysgeusia"]}}